Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

False Negative Results in Clostridium difficile Testing

Authors: Yanal M. Murad, Justo Perez, Gustavo Ybazeta, Sarah Mavin, Sebastien Lefebvre, J. Scott Weese, Joyce Rousseau, Francisco Diaz-Mitoma, Reza Nokhbeh

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Accurate diagnosis of Clostridium difficile infection (CDI) is paramount for patient management. The wrong diagnosis places patients at risk, delays treatment, and/ or contributes to transmission of infection in the healthcare setting. Although amplification of the toxin B gene by polymerase chain reaction (PCR) is a sensitive method for detecting toxigenic C. difficile, false negative results still occur and could impact the diagnosis and treatment of this infection.

Methods

This study investigated 48 patients that tested negative for toxigenic C. difficile via GeneXpert C. difficile epi test, while simultaneously testing positive for toxigenic C. difficile via stool culture. Fifty discrepant samples were collected over a 15-month period and all C. difficile isolates were characterized by ribotype. Patient charts were reviewed to assess whether discrepant results impacted the treatment course or clinical outcome of affected patients.

Results

Fifty samples of a total of 2308 samples tested in an acute healthcare facility over a 15-month period had negative PCR and positive stool culture for toxigenic C. difficile. C. difficile isolated from the discrepant samples resulted in diverse ribotyping patterns suggesting they were derived from different strains. The samples belonged to patients who were distributed evenly between age groups and wards in the hospital. In the majority of cases, the false negative C. difficile test results did not seem to impact the clinical outcome in these patients.

Conclusions

The PCR limit of detection may impact the results of molecular methods for C. difficile detection. Both clinical and analytical sensitivity of C. difficile tests should be considered when deciding which diagnostic assay to use, and clinical correlates should be examined carefully before excluding CDI as a cause of disease.
Literature
8.
12.
go back to reference Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47(10):3211–7. doi:10.1128/JCM.01082-09.CrossRefPubMedPubMedCentral Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47(10):3211–7. doi:10.​1128/​JCM.​01082-09.CrossRefPubMedPubMedCentral
13.
go back to reference Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55. doi:10.1086/651706.CrossRefPubMed Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55. doi:10.​1086/​651706.CrossRefPubMed
14.
go back to reference Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45(8):992–8. doi:10.1086/521854.CrossRefPubMed Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45(8):992–8. doi:10.​1086/​521854.CrossRefPubMed
15.
17.
go back to reference Cepheid. GeneXpert C. difficile/Epi product insert. 2012. Cepheid. GeneXpert C. difficile/Epi product insert. 2012.
19.
go back to reference Lemee L, Dhalluin A, Testelin S, Mattrat M, Maillard K, Pons J. Multiplex PCR Targeting tpi (Triose Phosphate Isomerase), tcdA (Toxin A), and tcdB (Toxin B). Genes for Toxigenic Culture of Clostridium difficile. 2004;2(12):5710–4. doi:10.1128/JCM.42.12.5710. Lemee L, Dhalluin A, Testelin S, Mattrat M, Maillard K, Pons J. Multiplex PCR Targeting tpi (Triose Phosphate Isomerase), tcdA (Toxin A), and tcdB (Toxin B). Genes for Toxigenic Culture of Clostridium difficile. 2004;2(12):5710–4. doi:10.​1128/​JCM.​42.​12.​5710.
20.
go back to reference Bidet P, Petit J. Development of a new PCR-ribotyping method for Clostridium di ¤ cile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett. 1999;175:261–6.CrossRefPubMed Bidet P, Petit J. Development of a new PCR-ribotyping method for Clostridium di ¤ cile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett. 1999;175:261–6.CrossRefPubMed
25.
go back to reference Dionne L-L, Raymond F, Corbeil J, Longtin J, Gervais P, Longtin Y. Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. J Clin Microbiol. 2013;51(11):3624–30. doi:10.1128/JCM.01444-13.CrossRefPubMedPubMedCentral Dionne L-L, Raymond F, Corbeil J, Longtin J, Gervais P, Longtin Y. Correlation between Clostridium difficile bacterial load, commercial real-time PCR cycle thresholds, and results of diagnostic tests based on enzyme immunoassay and cell culture cytotoxicity assay. J Clin Microbiol. 2013;51(11):3624–30. doi:10.​1128/​JCM.​01444-13.CrossRefPubMedPubMedCentral
27.
go back to reference Sunkesula VCK, Kundrapu S, Muganda C, Sethi AK, Donskey CJ. Does empirical Clostridium difficile Infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin Infect Dis. 2013;57(4):494–500. doi:10.1093/cid/cit286.CrossRefPubMed Sunkesula VCK, Kundrapu S, Muganda C, Sethi AK, Donskey CJ. Does empirical Clostridium difficile Infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin Infect Dis. 2013;57(4):494–500. doi:10.​1093/​cid/​cit286.CrossRefPubMed
Metadata
Title
False Negative Results in Clostridium difficile Testing
Authors
Yanal M. Murad
Justo Perez
Gustavo Ybazeta
Sarah Mavin
Sebastien Lefebvre
J. Scott Weese
Joyce Rousseau
Francisco Diaz-Mitoma
Reza Nokhbeh
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-1741-6

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.